1093868-91-7

Upstream product

• 71171-94-3 2-(4-Fluorophenyl)-4,4-dimethyl-4,5-dihydro-oxazole 
• 459-57-4 4-fluorobenzaldehyde 
• 104283-70-7 4,4-dimethyl-2-(4-fluorophenyl)oxazoline 
• 1006-41-3 2-bromo-4-fluorobenzoic acid 
• 124-68-5 2-Amino-2-methyl-1-propanol 
• 95383-36-1 2-bromo-4-fluorobenzoyl chloride 

Downstream Products

• 1093868-92-8 tert-butyl 3-(2-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-5-fluorophenyl)-3-oxopropyl(methyl)carbamate 
• 1093869-25-0 C₃₂H₅₁FN₄O₅ 
• 1093868-46-2 3-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)-1-(2-((S)-6-fluoro-1-(4-methoxybutyl)-3-oxoisoindolin-1-yl)ethyl)-1-methylurea 

Relevant academic research and scientific papers

Directed functionalization of halophenyl-2-oxazolines with TMPMgCl?LiCl

A variety of difunctionalized aryl-2-oxazolines were prepared from the reaction of halophenyl-2-oxazolines and TMPMgCl?LiCl to give an organomagnesium reagent, which was then treated with various electrophiles. The metalation step takes place under mild conditions, and this process al-lows for the isolation of the desired products in good yields. No isomeric or other benzyne-derived products were detected. The influence of the halogen substituents on the acidity of the aromatic hydrogen atoms was evaluated by using density functional theory (DFT) calculations.

RENIN INHIBITORS

The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagon